Related references
Note: Only part of the references are listed.
Article
Clinical Neurology
Madhav Thambisetty et al.
Summary: The phase III Clarity AD clinical trial found that the amyloid-targeting antibody, lecanemab, has a slight clinical benefit for individuals with Alzheimer's disease. However, there are still uncertainties about the actual clinical relevance, safety, and accessibility of lecanemab in this patient population.
NATURE REVIEWS NEUROLOGY
(2023)
Article
Medicine, General & Internal
Christopher H. van Dyck et al.
Summary: Lecanemab, a humanized monoclonal antibody, reduced amyloid markers and showed improvement in cognition and function in early Alzheimer's disease patients. However, it also resulted in adverse events. Longer trials are needed to determine its efficacy and safety in early Alzheimer's disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Clinical Neurology
Francesca Alves et al.
Summary: This study evaluates the brain volume changes caused by different subclasses of anti-beta-amyloid drugs in Alzheimer patients. The findings suggest that these drugs may accelerate brain atrophy and have varying effects on different brain regions.
Letter
Medicine, General & Internal
Julia Cave Arbanas et al.
Summary: This study utilizes data from the 2018 Health and Retirement Study to analyze the potential future Medicare spending and beneficiary costs associated with lecanemab.
JAMA INTERNAL MEDICINE
(2023)
Article
Medicine, General & Internal
John R. Sims et al.
Summary: This study evaluated the efficacy and adverse events of donanemab, an antibody treatment for Alzheimer's disease. The findings showed that donanemab significantly slowed disease progression in patients with early symptomatic Alzheimer's disease.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, General & Internal
John R. Sims et al.
Summary: This study assessed the efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. The results showed that donanemab significantly slowed the clinical progression in individuals with early symptomatic Alzheimer disease and low/medium tau pathology, as well as in the combined population with low/medium and high tau pathology.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Clinical Neurology
Eric L. Ross et al.
Summary: The study estimated that neither aducanumab nor donanemab would be cost-effective for early AD in the US at current expected prices. The dosing scheme of donanemab, where treatment is suspended upon achieving substantial amyloid reductions, may provide a standard by which sufficiently effective anti-amyloid antibody treatments could be cost-effective even when priced comparably to other biologics.
Editorial Material
Medicine, General & Internal
G. Caleb Alexander et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Michael G. Nanna et al.
JAMA INTERNAL MEDICINE
(2020)
Editorial Material
Medicine, General & Internal
Marie A. Bernard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2018)
